P221 Non-cirrhotic vs Cirrhotic HCC: comparison between patient characteristics, aetiology and outcomes

Abstract

6% rivaroxaban. Duration of anticoagulation could be ascertained in 28 patients: 43% had 6 months, 39% lifelong, 7% had 4 months and the other 3 cases separately had 6 weeks, 2 months and 12 months.Of the 51 patients who survived >6 months after diagnosis 59% had repeat CT imaging. The majority (n=23) were anticoagulated and there was recanalisation in 61%, partial recanalisation in 13% and cavernous transformation in 26%. 83% of those with cavernous transformation had portal hypertension.6 of the non-anticoagulated cases had a repeat CT. 1 had partial recanalisation and had developed varices. The other 5 had recanalisation but notably these cases were non-occlusive aPVT. Conclusions This audit highlighted inconsistencies in the management of non-cirrhotic, non-malignant aPVT in our centre. On assessment of recanalisation several cases had cavernous transformation and resultant portal hypertension but many did not get this assessment and so their risk of portal hypertension is unknown.As a result of these findings we are developing an aPVT pathway to guide clinicians, minimise complications of aPVT and develop a consistent approach in our trust.

Etiologic fractions in patients of hepatocellular carcinoma in India with and without a background of cirrhosis: a multi-centric study

“…13 Non-cirrhotic HCC patients were older at diagnosis as compared to cirrhotic HCC but had a similar male to female ratio. A similar nding in demographic pro le was observed by Tham et al 14 Of all HCC patients in our study, non-cirrhotic HCC accounted for 27.9%, while the remainder had a background of cirrhosis. In various other studies done worldwide, cirrhosis was reported in 60-99% of patients with HCC.…”

The Performance of a Survival Nomogram and Albumin–Bilirubin Grade as Prognostic Tools in Advanced Hepatocellular Carcinoma Treated with FOLFOX4

“…The prevalence of cirrhosis was notably higher (90.8%) in the present study compared with 55% in the EACH study. Cirrhosis is a pivotal factor affecting the survival of patients with HCC [20][21][22], with decompensated cirrhosis contributing to poorer prognosis, owing to both cirrhosis itself and decreased chemotherapy tolerability among these patients [23,24]. Furthermore, the rates of CTP B (26.3%) and ascites (10.5%) were higher in the present study compared with the EACH study (11.0% and 3.3%, respectively), further highlighting the increased risk of decompensated cirrhosis in our patient cohort.…”